美国地方药品监管机构推行药品电子谱系的困惑与启示

梁建军; 栾智鹏; 陈盛新; 梁建军; 栾智鹏; 陈盛新

doi:10.3969/j.issn.1006-0111.2013.03.023

[1]

U.S. FDA. FDA 2006 Compliance Policy Guide for the Prescription Drug Marketing Act [EB/OL]. http://www.fda.gov/OHRMS/DOCKETS/98fr/06-9211.htm. 2006-11-15.

[2]

Board of Pharmacy, State of California. Background and Summary of the California ePedigree Law[EB/OL]. http://www.pharmacy.ca.gov/laws_regs/e_pedigree_laws_summary.pdf.

[3]

U.S. FDA. Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs[EB/OL]. http://www.fda.gov/oc/initiatives/counterfeit/rfid_cpg.html.2004-11-01.

[4]

U.S. FDA. Compliance Policy Guide[EB/OL]. http://www.fda.gov/ICECI/ComplianceManuals/CompliancePolicyGuidanceManual/ucm074357.htm.2004-11-01.

[5]

Board of Pharmacy, State of California. California E——Pedigree Law[EB/OL]. http://www.pharmacy.ca.gov/about/e_pedigree_laws.shtml.

[6]

Claire Swedberg. GS1 Group Completes Early Phase of E-Pedigree Model[EB/OL]. http://www.rfidjournal.com/articles/view?7605. 2010-05-19.